The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes
Yıl: 2023 Cilt: 47 Sayı: 4 Sayfa Aralığı: 262 - 275 Metin Dili: İngilizce DOI: 10.55730/1300-0152.2661 İndeks Tarihi: 20-11-2023
The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes
Öz: Background/aim: The role of PD-L1 in regulating the immunosuppressive tumor microenvironment via its binding on PD-1 receptors is extensively studied. The PD-1/PD-L1 axis is a significant way of cancer immune escape, and PD-L1 expression on tumor cells is suggested as a predictive marker for anti-PD-1/PD-L1 monoclonal antibodies (MoAbs). However, the tumor-intrinsic role of PD- L1 is not known well. Therefore, we aimed to investigate the effects of anti-PD-L1 antibodies on the expression of angiogenesis and metastasis-related genes in tumor cells. Materials and methods: The experiments were done with prostate cancer and melanoma cells with low PD-L1 expression (<5%) and prostate and breast cancer cells with high PD-L1 expression (>50%). The gene and protein expressions of VEGFA, E-cadherin, TGFβ1, EGFR, and bFGF in tumor cells were assayed at the 3 different doses of the anti-PD-L1 antibody. Results: We found that VEGFA, E-cadherin and TGFβ1 expressions increased in PD-L1 high cells but decreased in PD-L1 low cells after anti-PD-L1 treatment. EGFR expression levels were variable in PD-L1 high cells, while decreased in PD-L1 low cells upon treatment. Also, the anti-PD-L1 antibody was found to increase bFGF expression in the prostate cancer cell line with high PD-L1 expression. Conclusion: Our results suggest that the binding of PD-L1 on tumor cells by an anti-PD-L1 monoclonal antibody may affect tumor- intrinsic mechanisms. The activation of angiogenesis and metastasis-related pathways by anti-PD-L1 treatment in PD-L1 high tumors might be a tumor-promoting mechanism. The decrease of VEGFA, TGFβ1 and EGFR upon anti-PD-L1 treatment in PD-L1 low tumor cells provides a rationale for the use of those antibodies in PD-L1 low tumors.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Akinleye A, Rasool Z (2019). Immune checkpoint inhibitors of PD- L1 as cancer therapeutics. Journal of Hematology & Oncology, 12 (1): 92. https://doi.org/10.1186/s13045-019-0779-5
- Akl MR, Nagpal P, Ayoub NM, Tai B, Prabhu SA et al. (2016). Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget, 7 (28): 44735- 44762. https://doi.org/10.18632/oncotarget.8203
- Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R et al. (2017). Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med, 9 (385). https://doi.org/10.1126/scitranslmed.aak9679
- Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A et al. (2015). Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin- low breast cancer cells. Molecular Cancer, 14 (1): 149. https:// doi.org/10.1186/s12943-015-0421-2
- Bai R, Chen N, Li L, Du N, Bai L et al. (2020). Mechanisms of Cancer Resistance to Immunotherapy. Front Oncol, 10: 1290. https:// doi.org/10.3389/fonc.2020.01290
- Bourhis M, Palle J, Galy-Fauroux I, Terme M (2021). Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment. Front Immunol, 12, 616837. https://doi.org/10.3389/fimmu.2021.616837
- Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL et al. (2015). Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res, 3 (10): 1148-1157. https:// doi.org/10.1158/2326-6066.Cir-15-0059
- Ciciola P, Cascetta P, Bianco C, Formisano L, Bianco R (2020). Combining Immune Checkpoint Inhibitors with Anti- Angiogenic Agents. J Clin Med, 9 (3). https://doi.org/10.3390/ jcm9030675
- Dong P, Xiong Y, Yue J, Hanley SJB, Watari H (2018). Tumor- Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion. Front Oncol, 8:386. https://doi.org/10.3389/fonc.2018.00386
- Eslami Amirabadi H, Tuerlings M, Hollestelle A, SahebAli S, Luttge R et al. (2019). Characterizing the invasion of different breast cancer cell lines with distinct E-cadherin status in 3D using a microfluidic system. Biomed Microdevices, 21 (4): 101. https:// doi.org/10.1007/s10544-019-0450-5
- French JJ, Cresswell J, Wong WK, Seymour K, Charnley RM et al. (2002). T cell adhesion and cytolysis of pancreatic cancer cells: a role for E-cadherin in immunotherapy? Br J Cancer, 87 (9): 1034-1041. https://doi.org/10.1038/sj.bjc.6600597
- Ghebeh H, Lehe C, Barhoush E, Al-Romaih K, Tulbah A et al. (2010). Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res, 12 (4): R48. https://doi.org/10.1186/bcr2605
- Holmgaard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY et al. (2018). Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J Immunother Cancer, 6 (1): 47. https://doi.org/10.1186/s40425- 018-0356-4
- Jenkins RW, Barbie DA, Flaherty KT (2018). Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer, 118 (1): 9-16. https://doi.org/10.1038/bjc.2017.434
- Jiang S, Liu X, Li D, Yan M, Ju C et al. (2018). Study on Attenuating Angiogenesis and Epithelial-Mesenchymal Transition (EMT) of Non-Small Cell Lung Carcinoma (NSCLC) by Regulating MAGEC2. Technol Cancer Res Treat, 17, 1533033818797587. https://doi.org/10.1177/1533033818797587
- Ju X, Zhang H, Zhou Z, Wang Q (2020). Regulation of PD- L1 expression in cancer and clinical implications in immunotherapy. Am J Cancer Res, 10 (1): 1-11.
- Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR et al. (2007). The morphologies of breast cancer cell lines in three- dimensional assays correlate with their profiles of gene expression. Mol Oncol, 1 (1): 84-96. https://doi.org/10.1016/j. molonc.2007.02.004
- Kim S, Koh J, Kim MY, Kwon D, Go H et al. (2016). PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Hum Pathol, 58: 7-14. https://doi. org/10.1016/j.humpath.2016.07.007
- Knudson KM, Hicks KC, Luo X, Chen JQ, Schlom J et al. (2018). M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. Oncoimmunology, 7 (5), e1426519. https://doi.org/10.1080/2162402x.2018.1426519
- Korc M, Friesel RE (2009). The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets, 9 (5): 639-651. https://doi.org/10.2174/156800909789057006
- Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I et al. (2016). Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. Int J Oncol, 48 (5): 1825-1836. https://doi. org/10.3892/ijo.2016.3419
- Li F, Zhu T, Yue Y, Zhu X, Wang J et al. (2018). Preliminary mechanisms of regulating PD-L1 expression in non-small cell lung cancer during the EMT process. Oncol Rep, 40 (2): 775- 782. https://doi.org/10.3892/or.2018.6474
- Li X, Lian Z, Wang S, Xing L, Yu J (2018). Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC. Cancer Lett, 418: 1-9. https://doi.org/10.1016/j. canlet.2018.01.005
- Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J et al. (2020). Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances. J Immunother Cancer, 8 (1). https://doi. org/10.1136/jitc-2019-000433
- Liu S, Qin T, Jia Y, Li K (2019). PD-L1 Expression Is Associated With VEGFA and LADC Patients’ Survival. Front Oncol, 9, 189. https://doi.org/10.3389/fonc.2019.00189
- Lou Y, Diao L, Cuentas ER, Denning WL, Chen L et al. (2016). Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res, 22(14): 3630-3642. https://doi.org/10.1158/1078-0432.Ccr-15-1434
- Manzoni M, Rovati B, Ronzoni M, Loupakis F, Mariucci S et al. (2010). Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology, 79 (3-4): 187-196. https://doi.org/10.1159/000320609
- Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K et al. (2018). TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature, 554 (7693): 544-548. https://doi.org/10.1038/nature25501
- McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI et al. (2018). Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med, 24 (6): 749-757. https://doi.org/10.1038/s41591-018-0053-3
- Meder L, Schuldt P, Thelen M, Schmitt A, Dietlein F et al. (2018). Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. Cancer Res, 78 (15): 4270-4281. https://doi. org/10.1158/0008-5472.Can-17-2176
- Nakamoto T, Chang CS, Li AK, Chodak GW (1992). Basic fibroblast growth factor in human prostate cancer cells. Cancer Res, 52 (3): 571-577.
- Ock CY, Kim S, Keam B, Kim M, Kim TM et al. (2016). PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget, 7 (13): 15901-15914. https://doi.org/10.18632/oncotarget.7431
- Ramjiawan RR, Griffioen AW, Duda DG (2017). Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis, 20 (2): 185-204. https://doi. org/10.1007/s10456-017-9552-y
- Ravi R, Noonan KA, Pham V, Bedi R, Zhavoronkov A et al. (2018). Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy. Nature Communications, 9 (1): 741. https://doi.org/10.1038/s41467-017-02696-6
- Ren D, Hua Y, Yu B, Ye X, He Z et al. (2020). Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer, 19 (1): 19. https://doi. org/10.1186/s12943-020-1144-6
- Ribatti D, Tamma R, Annese T (2020). Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. Transl Oncol, 13 (6), 100773. https://doi.org/10.1016/j.tranon.2020.100773
- Russell PJ, Bennett S, Joshua A, Yu Y, Downing SR et al. (1999). Elevated expression of FGF-2 does not cause prostate cancer progression in LNCaP cells. The Prostate, 40 (1): 1-13. https:// doi.org/10.1002/(SICI)1097-0045(19990615)40:1<1::AID- PROS1>3.0.CO;2-K
- Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M et al. (2019). PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. J Cell Physiol, 234 (10): 16824-16837. https:// doi.org/10.1002/jcp.28358
- Sasada T, Azuma K, Ohtake J, Fujimoto Y (2016). Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment. Front Pharmacol, 7, 405. https://doi.org/10.3389/fphar.2016.00405
- Shields BD, Koss B, Taylor EM, Storey AJ, West KL et al. (2019). Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. Cancer Res, 79 (6): 1113-1123. https://doi.org/10.1158/0008- 5472.Can-18-1722
- Suda K, Rozeboom L, Rivard CJ, Yu H, Ellison K et al. (2017). Therapy- induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer, 109: 1-8. https://doi.org/10.1016/j.lungcan.2017.04.010
- Tamura R, Tanaka T, Akasaki Y, Murayama Y, Yoshida K et al. (2019). The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Medical Oncology, 37 (1): 2. https://doi.org/10.1007/s12032-019-1329-2
- Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N et al. (2013). VEGFA-VEGFR pathway blockade inhibits tumor- induced regulatory T-cell proliferation in colorectal cancer. Cancer Res, 73 (2): 539-549. https://doi.org/10.1158/0008- 5472.Can-12-2325
- van de Wetering M, Barker N, Harkes IC, van der Heyden M, Dijk NJ et al. (2001). Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. Cancer Res, 61 (1): 278-284.
- Wang W, Wang L, Mizokami A, Shi J, Zou C et al. (2017). Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chin J Cancer, 36 (1): 35. https://doi.org/10.1186/s40880-017-0203-x
- Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E (1989). Differential effects of transforming growth factor β on human prostate cancer cells in vitro. Molecular and Cellular Endocrinology, 62 (1): 79-87. https://doi.org/https://doi. org/10.1016/0303-7207(89)90115-9
- Wu Y, Chen W, Xu ZP, Gu W (2019). PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition. Front Immunol, 10, 2022. https:// doi.org/10.3389/fimmu.2019.02022
- Yi M, Jiao D, Qin S, Chu Q, Wu K et al. (2019). Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer, 18 (1): 60. https://doi.org/10.1186/ s12943-019-0974-6
- Yu W, Hua Y, Qiu H, Hao J, Zou K et al. (2020). PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death & Disease, 11 (7): 506. https://doi.org/10.1038/ s41419-020-2701-z
- Zhang M, Sun H, Zhao S, Wang Y, Pu H et al. (2017). Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget, 8 (19): 31347-31354. https://doi.org/10.18632/ oncotarget.15532
- Zhang Q, Rubenstein JN, Jang TL, Pins M, Javonovic B et al. (2005). Insensitivity to transforming growth factor-beta results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP). Mol Endocrinol, 19 (9): 2390-2399. https://doi.org/10.1210/me.2005-0096
- Zhang W, Pang Q, Yan C, Wang Q, Yang J et al. (2017). Induction of PD-L1 expression by epidermal growth factor receptor- mediated signaling in esophageal squamous cell carcinoma. Onco Targets Ther, 10: 763-771. https://doi.org/10.2147/ott. S118982
| APA | Babahan C, Abdi Abgarmi S, SONUGÜR F, Ocal-Demirtas M, Akbulut H (2023). The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes. , 262 - 275. 10.55730/1300-0152.2661 |
| Chicago | Babahan Cansu,Abdi Abgarmi Samira,SONUGÜR FATMA GİZEM,Ocal-Demirtas Muge,Akbulut Hakan The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes. (2023): 262 - 275. 10.55730/1300-0152.2661 |
| MLA | Babahan Cansu,Abdi Abgarmi Samira,SONUGÜR FATMA GİZEM,Ocal-Demirtas Muge,Akbulut Hakan The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes. , 2023, ss.262 - 275. 10.55730/1300-0152.2661 |
| AMA | Babahan C,Abdi Abgarmi S,SONUGÜR F,Ocal-Demirtas M,Akbulut H The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes. . 2023; 262 - 275. 10.55730/1300-0152.2661 |
| Vancouver | Babahan C,Abdi Abgarmi S,SONUGÜR F,Ocal-Demirtas M,Akbulut H The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes. . 2023; 262 - 275. 10.55730/1300-0152.2661 |
| IEEE | Babahan C,Abdi Abgarmi S,SONUGÜR F,Ocal-Demirtas M,Akbulut H "The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes." , ss.262 - 275, 2023. 10.55730/1300-0152.2661 |
| ISNAD | Babahan, Cansu vd. "The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes". (2023), 262-275. https://doi.org/10.55730/1300-0152.2661 |
| APA | Babahan C, Abdi Abgarmi S, SONUGÜR F, Ocal-Demirtas M, Akbulut H (2023). The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes. Turkish Journal of Biology, 47(4), 262 - 275. 10.55730/1300-0152.2661 |
| Chicago | Babahan Cansu,Abdi Abgarmi Samira,SONUGÜR FATMA GİZEM,Ocal-Demirtas Muge,Akbulut Hakan The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes. Turkish Journal of Biology 47, no.4 (2023): 262 - 275. 10.55730/1300-0152.2661 |
| MLA | Babahan Cansu,Abdi Abgarmi Samira,SONUGÜR FATMA GİZEM,Ocal-Demirtas Muge,Akbulut Hakan The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes. Turkish Journal of Biology, vol.47, no.4, 2023, ss.262 - 275. 10.55730/1300-0152.2661 |
| AMA | Babahan C,Abdi Abgarmi S,SONUGÜR F,Ocal-Demirtas M,Akbulut H The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes. Turkish Journal of Biology. 2023; 47(4): 262 - 275. 10.55730/1300-0152.2661 |
| Vancouver | Babahan C,Abdi Abgarmi S,SONUGÜR F,Ocal-Demirtas M,Akbulut H The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes. Turkish Journal of Biology. 2023; 47(4): 262 - 275. 10.55730/1300-0152.2661 |
| IEEE | Babahan C,Abdi Abgarmi S,SONUGÜR F,Ocal-Demirtas M,Akbulut H "The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes." Turkish Journal of Biology, 47, ss.262 - 275, 2023. 10.55730/1300-0152.2661 |
| ISNAD | Babahan, Cansu vd. "The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes". Turkish Journal of Biology 47/4 (2023), 262-275. https://doi.org/10.55730/1300-0152.2661 |
